Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sara Harcharik"'
Publikováno v:
JAAD Case Reports, Vol 4, Iss 1, Pp 58-60 (2018)
Externí odkaz:
https://doaj.org/article/c645637f10f14efd9bf857c5f9546c5a
Autor:
Philip Friedlander, William K. Oh, John Kirkwood, David Fisher, Karl Wassmann, Yichun Fu, Sara Harcharik, Ellen de Moll, Bobby Liaw, Jay Magidson, Yvonne Saenger
Supplementary Table 1 and 2. Table S1 contains all of the genes tested. Table S2 describes patient selection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::945e7a3fe58961325526fc2aa343203c
https://doi.org/10.1158/1078-0432.22450721
https://doi.org/10.1158/1078-0432.22450721
Autor:
Philip Friedlander, William K. Oh, John Kirkwood, David Fisher, Karl Wassmann, Yichun Fu, Sara Harcharik, Ellen de Moll, Bobby Liaw, Jay Magidson, Yvonne Saenger
Purpose: Tremelimumab (ticilimumab, Pfizer), is a monoclonal antibody (mAb) targeting cytotoxic T lymphocyte–associated antigen-4 (CTLA-4). Ipilimumab (Yervoy, BMS), another anti-CTLA-4 antibody, is approved by the U.S. Federal Drug Administration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29db8ca29156dfc5f8d157e4296b96ec
https://doi.org/10.1158/1078-0432.c.6522014
https://doi.org/10.1158/1078-0432.c.6522014
Autor:
Philip Friedlander, William K. Oh, John Kirkwood, David Fisher, Karl Wassmann, Yichun Fu, Sara Harcharik, Ellen de Moll, Bobby Liaw, Jay Magidson, Yvonne Saenger
Figure S1 provides risk score for melanoma patients and normals.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a25c64120dbf14602e80a88a42a704
https://doi.org/10.1158/1078-0432.22450724.v1
https://doi.org/10.1158/1078-0432.22450724.v1
Autor:
Jacob Levitt, Adam J. Luber, Sebastian Bernardo, Sara Harcharik, Michael Pan, Marina Moskalenko
Publikováno v:
The Clinical Teacher. 11:436-441
Summary Background Safe venepuncture technique is a critical skill for health care professionals, to avoid accidental occupational injury. This study investigates whether watching an instructional video improves medical students’ ability to perform
Autor:
Emily Bernstein, Miriam B. Birge, Chen Chen, Zulekha A. Qadeer, David Valle-Garcia, Luis F. Duarte, Chiara Vardabasso, Sara Harcharik
Publikováno v:
The Journal of investigative dermatology
To the Editor ATRX is a member of the SWI/SNF family of chromatin remodelers, originally identified as mutated in patients with Alpha Thalassemia/Mental Retardation, X-linked syndrome. The protein product contains several highly conserved domains, in
Autor:
Harleen K. Sidhu, Philip Friedlander, Rui Chang, Shaily Shah, Michael Pan, Marina Moskalenko, Serge Sicular, Yvonne M. Saenger, Sebastian Bernardo, Sara Harcharik
Publikováno v:
Melanoma Research. 23:47-54
Melanoma is the deadliest form of skin cancer. Ipilimumab, a novel immunotherapy, is the first treatment shown to improve survival in patients with metastatic melanoma in large randomized controlled studies. The most concerning side effects reported
Publikováno v:
Psoriasis Forum. :152-163
The objective of this work was to conduct a systematic review of the frequency with which concomitant immunosuppressive medication(s) are used in patients receiving biologics who develop malignancy. We conducted a PubMed search using the term “mali
Publikováno v:
Cutis. 96(3)
Recognizing current trends and obstacles in melanoma clinical trial development is critical to future progress in this field. This article examines the melanoma research enterprise to identify changing trends and potential barriers to success. All tr
Autor:
Yvonne Saenger, John M. Kirkwood, Sara Harcharik, Jay Magidson, Karl Wassmann, Yichun Fu, Bobby Chi-Hung Liaw, Ellen H de Moll, Philip Friedlander, David E. Fisher, William Oh
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(12)
Purpose: Tremelimumab (ticilimumab, Pfizer), is a monoclonal antibody (mAb) targeting cytotoxic T lymphocyte–associated antigen-4 (CTLA-4). Ipilimumab (Yervoy, BMS), another anti-CTLA-4 antibody, is approved by the U.S. Federal Drug Administration